NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
Clinical Trials
367 trialsNCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT03016156 2026-04-14
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma
St. Jude Children's Research Hospital
Phase NA Terminated
NCT06685068 2026-04-14
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT05879627 2026-04-13
To Evaluate the Safety, Tolerance and Pharmacokinetics of BAT8007 for Injection in Patients With Advanced Solid Tumors
Bio-Thera Solutions
Phase 1 Terminated
NCT06130254 2026-04-09
Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05262530 2026-04-08
Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors
BioNTech SE
Phase 1/2 Terminated
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05023655 2026-03-17
Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation
Prisma Health-Upstate
Phase 2 Terminated
NCT06391918 2026-03-13
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
GenVivo, Inc.
Phase 1 Terminated
NCT05381909 2026-02-20
A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
BeOne Medicines
Phase 1 Terminated
NCT05100251 2026-02-17
Clinical Trial of WBC100 on Advanced Solid Tumor
Zhejiang University
Phase 1 Terminated
NCT05638334 2026-02-17
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
Servier
Phase 1 Terminated
NCT06331559 2026-02-09
Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT04166734 2026-02-04
MESO-PRIME
Royal Marsden NHS Foundation Trust
Phase 1 Terminated
NCT05756907 2026-02-03
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Sonnet BioTherapeutics
Phase 1/2 Terminated
NCT06771921 2026-01-30
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
Genmab
Phase 1/2 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT06929260 2026-01-22
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
AstraZeneca
Phase 1 Terminated
NCT07108140 2026-01-22
Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Terminated
NCT04617054 2026-01-21
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Nuvation Bio Inc.
Phase 2 Terminated
NCT05868915 2026-01-21
HV-101 for Patients With Advanced Solid Tumors
Hervor Therapeutics
Phase 1 Terminated
NCT06334783 2026-01-21
TIL for Patients With Advanced Solid Tumor
Hervor Therapeutics
Phase 1 Terminated
NCT06006923 2026-01-20
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Terminated
NCT06299761 2026-01-16
STARMAP
Boundless Bio, Inc.
Phase 1 Terminated
NCT06560632 2026-01-16
POLAR
Repare Therapeutics
Phase 1 Terminated
NCT03075527 2026-01-08
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04284488 2026-01-08
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT06198426 2025-12-30
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Terminated
NCT06391775 2025-12-26
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
Genmab
Phase 1/2 Terminated
NCT05012618 2025-12-24
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
Chugai Pharmaceutical
Phase 1 Terminated
NCT06488716 2025-12-24
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7759065 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Terminated
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT06509906 2025-12-18
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
Phase 1 Terminated
NCT03968653 2025-12-05
Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
Debiopharm International SA
Phase 1 Terminated
NCT05147272 2025-12-05
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Debiopharm International SA
Phase 1 Terminated
NCT05147350 2025-12-05
MINOTAUR
Debiopharm International SA
Phase 1 Terminated
NCT04276376 2025-12-01
ARIANES
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT06232408 2025-11-21
LIONS (PLK4 Inhibitor in Advanced Solid Tumors)
Repare Therapeutics
Phase 1 Terminated
NCT06289894 2025-11-21
A Study of BRY805 in Participants With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.
Phase 1 Terminated
NCT03770494 2025-11-04
A Study of LY3405105 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
NCT04668833 2025-10-31
ALI Post Radiation Therapy in Patients With Lung and Esophageal Canter
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04972110 2025-10-30
ATTACC
Repare Therapeutics
Phase 1/2 Terminated
NCT02597036 2025-10-23
A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT05859464 2025-10-20
A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1 Terminated
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT06336148 2025-10-15
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Phase 1 Terminated
NCT03522142 2025-10-09
A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies
Incyte Corporation
Phase 1 Terminated
NCT05976334 2025-10-06
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
Takeda
Phase 1 Terminated